Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer

International Journal of Medical Sciences

Volumn 8, Issue 5, 2011, Pages 406-412

  Tamura, Takao ^a,b   Kuwahara, Akiko ^b,c   Kadoyama, Kaori ^b,d   Yamamori, Motohiro ^b,c   Nishiguchi, Kohshi ^b,e   Inokuma, Tsubasa ^d   Takemoto, Yoshiji ^d   Chayahara, Naoko ^b   Okuno, Tatsuya ^b   Miki, Ikuya ^b   Fujishima, Yoshimi ^b   Sakaeda, Toshiyuki ^b,d  

^a KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Bolus injection; Constant infusion; Pharmacokinetics; UFT

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; TEGAFUR; URACIL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG EXPOSURE; HUMAN; JAPANESE; STEADY STATE;

EID: 84860390266     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8.406     Document Type: Article

References (36)

1. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-14.
2. Venook A. Critical evaluation of current treatments in meta-static colorectal cancer. Oncologist 2005; 10: 250-61.
3. Lee JJ, Chu E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 2007; 13: 276-81.
4. Sabharwal A, Kerr D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev Anticancer Ther 2007; 7: 477-87.
5. Bennouna J, Saunders M, Douillard JY. The role of UFT in metastatic colorectal cancer. Oncology 2009; 76: 301-10.
6. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-16.
7. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3617-27.
8. Méndez M, Alfonso PG, Pujol E, et al. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. Invest New Drugs 2005; 23: 243-51.
9. Delord J-P, Bennouna J, Artru P, et al. Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. Br J Cancer 2007; 97: 297-301.
10. Ishida H, Miyake Y, Fukunaga M, et al. A Feasibility Study of UFT/LV and Irinotecan (TEGAFIRI) in Advanced or Metastatic Colorectal Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. Jpn J Clin Oncol 2009; 39: 601-5.
11. Bajetta E, Di Bartolomeo M, Buzzoni R, et al. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer 2007; 96: 439-44.
12. Feliu J, Vicent JM, Garcia-Giro C, et al. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer 2004; 91: 1758-62.
13. Rosati G, Cordio S, Tucci A, et al. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or meta-static colorectal cancer in elderly patients. Oncology 2005; 69: 122-9.
14. Bennouna J, Perrier H, Paillot B, et al. A phase II study of oral uracil/ftorafur (UFTs) plus leucovorin combined with oxali platin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer 2006; 94: 69-73.
15. Chayahara N, Tamura T, Yamamori M, et al. Phase I and pharmacokinetic study of tegafururacil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. Am J Clin Oncol 2009; 32: 56-60.
16. Chu D, Gu J, Liu W, et al. Sensitive liquid chromatographic assay for the simultaneous determination of 5-fluorouracil and its prodrug, tegafur, in beagle dog plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 795: 377-82.
17. Miki I, Tamura T, Nakamura T, et al. Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther Drug Monit 2005; 27: 369-74.
18. Okuno T, Tamura T, Yamamori M, et al. Favorable genetic polymorphisms predictive of clinical outcome of chemoradio-therapy for Stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol 2007; 30: 252-7.
19. Sakaeda T, Yamamori M, Kuwahara A, et al. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther Drug Monit 2008; 30: 497-503.
20. Ho DH, Pazdur R, Covington W, et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 1998; 4: 2085-8.
21. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-58.
22. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharma-cokinetic monitoring in 152 patients. J Clin Oncol 1998; 16: 1470-8.
23. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 441-51.
24. Vokes EE, Mick R, Kies MS, et al. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 1996; 14: 1663-71.
25. Ychou M, Duffour J, Kramar A, et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol 2003; 52: 282-90.
26. Milano G, Etienne MC, Renée N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994; 12: 1291-5.
27. Hillcoat BL, McCulloch PB, Figueredo AT, et al. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 1978; 38: 719-24.
28. Seitz JF, Cano JP, Rigault JP, et al. Chemotherapy of extensive digestive cancers with 5-fluorouracil: relation between the clinical response and plasma clearance of the drug. Gastroenterol Clin Biol 1983; 7: 374-80.
29. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokineticallyguided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4: 2039-45.
30. Highlights from: 5-fluorouracil drug management pharmaco-kinetics and pharmacogenomics workshop; Orlando, Florida; January 2007. Clin Colorectal Cancer 2007; 6: 407-22.
31. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15: 368-81.
32. de Gramont A, Louvet C, André T, et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 1998; 34: 619-26.
33. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin. Oncol 2000; 18: 2938-47.
34. Köhne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003; 21: 3721-8.
35. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967-72.
36. Sakaeda T, Yamamori M, Kuwahara A, et al. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradio-therapy. Adv Drug Deliv Rev 2009; 61: 388-401.